Antifungal susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species from Taiwan

Surveillance of Multicenter Antimicrobial Resistance in Taiwan program data from 2003

Po Ren Hsueh, Yeu Jun Lau, Yin Ching Chuang, Jen Hsien Wan, Wen Kuei Huang, Jainn Ming Shyr, Jing Jou Yan, Kwok Woon Yu, Jiunn Jong Wu, Wen Chien Ko, Yi Chueh Yang, Yung Ching Liu, Lee Jene Teng, Cheng Yi Liu, Kwen Tay Luh

Research output: Contribution to journalArticle

81 Citations (Scopus)

Abstract

The susceptibilities of nonduplicate isolates to six antifungal agents were determined for 391 blood isolates of seven Candida species, 70 clinical isolates (from blood or cerebrospinal fluid) of Cryptococcus neoformans, and 96 clinical isolates of four Aspergillus species, which were collected in seven different hospitals in Taiwan (as part of the 2003 program of the study group Surveillance of Multicenter Antimicrobial Resistance in Taiwan). All isolates of Candida species other than C. glabrata and C. krusei were susceptible to fluconazole. Among the 59 C. glabrata isolates, 16 (27%) were not susceptible to fluconazole, and all were dose-dependently susceptible or resistant to itraconazole. For three (5.1%) C. glabrata isolates, voriconazole MICs were 2 to 4 μg/ml, and for all other Candida species isolates, voriconazole MICs were ≤0.5 μg/ml. The proportions of isolates for which amphotericin B MICs were ≥2 μg/ml were 100% (3 isolates) for C. krusei, 11% (23 of 207 isolates) for Candida albicans, 3.0% (2 of 67 isolates) for Candida tropicalis, 20% (12 of 59 isolates) for C. glabrata, and 0% for both Candida parapsilosis and Candida lusitaniae. For three (4%) Cryptococcus neoformans isolates, fluconazole MICs were ≥16 μg/ml, and two (3%) isolates were not inhibited by 1 μg of amphotericin B/ml. For four (4.2%) of the Aspergillus isolates, itraconazole MICs were 8 μg/ml. Aspergillus flavus was less susceptible to amphotericin B, with the MICs at which 50% (1 μ/ml) and 90% (2 μg/ml) nsrsid417869\delrsid7301351 of isolates were inhibited being twofold greater than those for Aspergillus fumigatus and Aspergillus niger. All Aspergillus isolates were inhibited by ≤1 μg of voriconazole/ml, including isolates with increased resistance to amphotericin B and itraconazole. This study revealed the emergence in Taiwan of decreased susceptibilities of Candida species to amphotericin B and of C. neoformans to fluconazole and amphotericin B. Voriconazole was the most potent agent against the fungal isolates tested, including fluconazole- and amphotericin B-nonsusceptible strains.

Original languageEnglish
Pages (from-to)512-517
Number of pages6
JournalAntimicrobial Agents and Chemotherapy
Volume49
Issue number2
DOIs
Publication statusPublished - Feb 2005
Externally publishedYes

Fingerprint

Cryptococcus neoformans
Amphotericin B
Aspergillus
Taiwan
Candida
Fluconazole
Itraconazole
Candida tropicalis
Aspergillus flavus
Aspergillus fumigatus
Aspergillus niger
Antifungal Agents
Candida albicans
Cerebrospinal Fluid
Voriconazole

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Antifungal susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species from Taiwan : Surveillance of Multicenter Antimicrobial Resistance in Taiwan program data from 2003. / Hsueh, Po Ren; Lau, Yeu Jun; Chuang, Yin Ching; Wan, Jen Hsien; Huang, Wen Kuei; Shyr, Jainn Ming; Yan, Jing Jou; Yu, Kwok Woon; Wu, Jiunn Jong; Ko, Wen Chien; Yang, Yi Chueh; Liu, Yung Ching; Teng, Lee Jene; Liu, Cheng Yi; Luh, Kwen Tay.

In: Antimicrobial Agents and Chemotherapy, Vol. 49, No. 2, 02.2005, p. 512-517.

Research output: Contribution to journalArticle

Hsueh, Po Ren ; Lau, Yeu Jun ; Chuang, Yin Ching ; Wan, Jen Hsien ; Huang, Wen Kuei ; Shyr, Jainn Ming ; Yan, Jing Jou ; Yu, Kwok Woon ; Wu, Jiunn Jong ; Ko, Wen Chien ; Yang, Yi Chueh ; Liu, Yung Ching ; Teng, Lee Jene ; Liu, Cheng Yi ; Luh, Kwen Tay. / Antifungal susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species from Taiwan : Surveillance of Multicenter Antimicrobial Resistance in Taiwan program data from 2003. In: Antimicrobial Agents and Chemotherapy. 2005 ; Vol. 49, No. 2. pp. 512-517.
@article{b97262477cdb46b295eb070a24177a64,
title = "Antifungal susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species from Taiwan: Surveillance of Multicenter Antimicrobial Resistance in Taiwan program data from 2003",
abstract = "The susceptibilities of nonduplicate isolates to six antifungal agents were determined for 391 blood isolates of seven Candida species, 70 clinical isolates (from blood or cerebrospinal fluid) of Cryptococcus neoformans, and 96 clinical isolates of four Aspergillus species, which were collected in seven different hospitals in Taiwan (as part of the 2003 program of the study group Surveillance of Multicenter Antimicrobial Resistance in Taiwan). All isolates of Candida species other than C. glabrata and C. krusei were susceptible to fluconazole. Among the 59 C. glabrata isolates, 16 (27{\%}) were not susceptible to fluconazole, and all were dose-dependently susceptible or resistant to itraconazole. For three (5.1{\%}) C. glabrata isolates, voriconazole MICs were 2 to 4 μg/ml, and for all other Candida species isolates, voriconazole MICs were ≤0.5 μg/ml. The proportions of isolates for which amphotericin B MICs were ≥2 μg/ml were 100{\%} (3 isolates) for C. krusei, 11{\%} (23 of 207 isolates) for Candida albicans, 3.0{\%} (2 of 67 isolates) for Candida tropicalis, 20{\%} (12 of 59 isolates) for C. glabrata, and 0{\%} for both Candida parapsilosis and Candida lusitaniae. For three (4{\%}) Cryptococcus neoformans isolates, fluconazole MICs were ≥16 μg/ml, and two (3{\%}) isolates were not inhibited by 1 μg of amphotericin B/ml. For four (4.2{\%}) of the Aspergillus isolates, itraconazole MICs were 8 μg/ml. Aspergillus flavus was less susceptible to amphotericin B, with the MICs at which 50{\%} (1 μ/ml) and 90{\%} (2 μg/ml) nsrsid417869\delrsid7301351 of isolates were inhibited being twofold greater than those for Aspergillus fumigatus and Aspergillus niger. All Aspergillus isolates were inhibited by ≤1 μg of voriconazole/ml, including isolates with increased resistance to amphotericin B and itraconazole. This study revealed the emergence in Taiwan of decreased susceptibilities of Candida species to amphotericin B and of C. neoformans to fluconazole and amphotericin B. Voriconazole was the most potent agent against the fungal isolates tested, including fluconazole- and amphotericin B-nonsusceptible strains.",
author = "Hsueh, {Po Ren} and Lau, {Yeu Jun} and Chuang, {Yin Ching} and Wan, {Jen Hsien} and Huang, {Wen Kuei} and Shyr, {Jainn Ming} and Yan, {Jing Jou} and Yu, {Kwok Woon} and Wu, {Jiunn Jong} and Ko, {Wen Chien} and Yang, {Yi Chueh} and Liu, {Yung Ching} and Teng, {Lee Jene} and Liu, {Cheng Yi} and Luh, {Kwen Tay}",
year = "2005",
month = "2",
doi = "10.1128/AAC.49.2.512-517.2005",
language = "English",
volume = "49",
pages = "512--517",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "2",

}

TY - JOUR

T1 - Antifungal susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species from Taiwan

T2 - Surveillance of Multicenter Antimicrobial Resistance in Taiwan program data from 2003

AU - Hsueh, Po Ren

AU - Lau, Yeu Jun

AU - Chuang, Yin Ching

AU - Wan, Jen Hsien

AU - Huang, Wen Kuei

AU - Shyr, Jainn Ming

AU - Yan, Jing Jou

AU - Yu, Kwok Woon

AU - Wu, Jiunn Jong

AU - Ko, Wen Chien

AU - Yang, Yi Chueh

AU - Liu, Yung Ching

AU - Teng, Lee Jene

AU - Liu, Cheng Yi

AU - Luh, Kwen Tay

PY - 2005/2

Y1 - 2005/2

N2 - The susceptibilities of nonduplicate isolates to six antifungal agents were determined for 391 blood isolates of seven Candida species, 70 clinical isolates (from blood or cerebrospinal fluid) of Cryptococcus neoformans, and 96 clinical isolates of four Aspergillus species, which were collected in seven different hospitals in Taiwan (as part of the 2003 program of the study group Surveillance of Multicenter Antimicrobial Resistance in Taiwan). All isolates of Candida species other than C. glabrata and C. krusei were susceptible to fluconazole. Among the 59 C. glabrata isolates, 16 (27%) were not susceptible to fluconazole, and all were dose-dependently susceptible or resistant to itraconazole. For three (5.1%) C. glabrata isolates, voriconazole MICs were 2 to 4 μg/ml, and for all other Candida species isolates, voriconazole MICs were ≤0.5 μg/ml. The proportions of isolates for which amphotericin B MICs were ≥2 μg/ml were 100% (3 isolates) for C. krusei, 11% (23 of 207 isolates) for Candida albicans, 3.0% (2 of 67 isolates) for Candida tropicalis, 20% (12 of 59 isolates) for C. glabrata, and 0% for both Candida parapsilosis and Candida lusitaniae. For three (4%) Cryptococcus neoformans isolates, fluconazole MICs were ≥16 μg/ml, and two (3%) isolates were not inhibited by 1 μg of amphotericin B/ml. For four (4.2%) of the Aspergillus isolates, itraconazole MICs were 8 μg/ml. Aspergillus flavus was less susceptible to amphotericin B, with the MICs at which 50% (1 μ/ml) and 90% (2 μg/ml) nsrsid417869\delrsid7301351 of isolates were inhibited being twofold greater than those for Aspergillus fumigatus and Aspergillus niger. All Aspergillus isolates were inhibited by ≤1 μg of voriconazole/ml, including isolates with increased resistance to amphotericin B and itraconazole. This study revealed the emergence in Taiwan of decreased susceptibilities of Candida species to amphotericin B and of C. neoformans to fluconazole and amphotericin B. Voriconazole was the most potent agent against the fungal isolates tested, including fluconazole- and amphotericin B-nonsusceptible strains.

AB - The susceptibilities of nonduplicate isolates to six antifungal agents were determined for 391 blood isolates of seven Candida species, 70 clinical isolates (from blood or cerebrospinal fluid) of Cryptococcus neoformans, and 96 clinical isolates of four Aspergillus species, which were collected in seven different hospitals in Taiwan (as part of the 2003 program of the study group Surveillance of Multicenter Antimicrobial Resistance in Taiwan). All isolates of Candida species other than C. glabrata and C. krusei were susceptible to fluconazole. Among the 59 C. glabrata isolates, 16 (27%) were not susceptible to fluconazole, and all were dose-dependently susceptible or resistant to itraconazole. For three (5.1%) C. glabrata isolates, voriconazole MICs were 2 to 4 μg/ml, and for all other Candida species isolates, voriconazole MICs were ≤0.5 μg/ml. The proportions of isolates for which amphotericin B MICs were ≥2 μg/ml were 100% (3 isolates) for C. krusei, 11% (23 of 207 isolates) for Candida albicans, 3.0% (2 of 67 isolates) for Candida tropicalis, 20% (12 of 59 isolates) for C. glabrata, and 0% for both Candida parapsilosis and Candida lusitaniae. For three (4%) Cryptococcus neoformans isolates, fluconazole MICs were ≥16 μg/ml, and two (3%) isolates were not inhibited by 1 μg of amphotericin B/ml. For four (4.2%) of the Aspergillus isolates, itraconazole MICs were 8 μg/ml. Aspergillus flavus was less susceptible to amphotericin B, with the MICs at which 50% (1 μ/ml) and 90% (2 μg/ml) nsrsid417869\delrsid7301351 of isolates were inhibited being twofold greater than those for Aspergillus fumigatus and Aspergillus niger. All Aspergillus isolates were inhibited by ≤1 μg of voriconazole/ml, including isolates with increased resistance to amphotericin B and itraconazole. This study revealed the emergence in Taiwan of decreased susceptibilities of Candida species to amphotericin B and of C. neoformans to fluconazole and amphotericin B. Voriconazole was the most potent agent against the fungal isolates tested, including fluconazole- and amphotericin B-nonsusceptible strains.

UR - http://www.scopus.com/inward/record.url?scp=19944432456&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=19944432456&partnerID=8YFLogxK

U2 - 10.1128/AAC.49.2.512-517.2005

DO - 10.1128/AAC.49.2.512-517.2005

M3 - Article

VL - 49

SP - 512

EP - 517

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 2

ER -